KR102229108B1 - 생세포를 포함하는 생물학적 약물을 처리하기 위한 방법 - Google Patents

생세포를 포함하는 생물학적 약물을 처리하기 위한 방법 Download PDF

Info

Publication number
KR102229108B1
KR102229108B1 KR1020137032016A KR20137032016A KR102229108B1 KR 102229108 B1 KR102229108 B1 KR 102229108B1 KR 1020137032016 A KR1020137032016 A KR 1020137032016A KR 20137032016 A KR20137032016 A KR 20137032016A KR 102229108 B1 KR102229108 B1 KR 102229108B1
Authority
KR
South Korea
Prior art keywords
cells
delete delete
hours
buffer
nutritional
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020137032016A
Other languages
English (en)
Korean (ko)
Other versions
KR20140043367A (ko
Inventor
마이클 하-노이
Original Assignee
이뮤노베이티브 테라피스, 엘티디.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 이뮤노베이티브 테라피스, 엘티디. filed Critical 이뮤노베이티브 테라피스, 엘티디.
Publication of KR20140043367A publication Critical patent/KR20140043367A/ko
Application granted granted Critical
Publication of KR102229108B1 publication Critical patent/KR102229108B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/12—Chemical aspects of preservation
    • A01N1/122—Preservation or perfusion media
    • A01N1/126—Physiologically active agents, e.g. antioxidants or nutrients
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/14—Mechanical aspects of preservation; Apparatus or containers therefor
    • A01N1/146—Non-refrigerated containers specially adapted for transporting or storing living parts whilst preserving
    • A01N1/148—Non-refrigerated containers specially adapted for transporting or storing living parts whilst preserving with provisions specially adapted for transporting
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
    • B65B1/00—Packaging fluent solid material, e.g. powders, granular or loose fibrous material, loose masses of small articles, in individual containers or receptacles, e.g. bags, sacks, boxes, cartons, cans, or jars
    • B65B1/04—Methods of, or means for, filling the material into the containers or receptacles
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N15/14—Optical investigation techniques, e.g. flow cytometry
    • G01N15/149—Optical investigation techniques, e.g. flow cytometry specially adapted for sorting particles, e.g. by their size or optical properties
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6866—Interferon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/555—Interferons [IFN]
    • G01N2333/57—IFN-gamma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30 CD40 or CD95

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Environmental Sciences (AREA)
  • Mechanical Engineering (AREA)
  • Dermatology (AREA)
KR1020137032016A 2011-05-03 2012-05-02 생세포를 포함하는 생물학적 약물을 처리하기 위한 방법 Active KR102229108B1 (ko)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201161481991P 2011-05-03 2011-05-03
US61/481,991 2011-05-03
US201161528493P 2011-08-29 2011-08-29
US61/528,493 2011-08-29
US201161565225P 2011-11-30 2011-11-30
US61/565,225 2011-11-30
US201261582878P 2012-01-04 2012-01-04
US61/582,878 2012-01-04
PCT/US2012/036103 WO2012151266A1 (en) 2011-05-03 2012-05-02 Methods for handling biological drugs containing living cells

Related Child Applications (2)

Application Number Title Priority Date Filing Date
KR1020147019539A Division KR20140099328A (ko) 2011-05-03 2012-05-02 생세포를 포함하는 생물학적 약물을 처리하기 위한 용기 또는 주사기
KR1020197020882A Division KR102202460B1 (ko) 2011-05-03 2012-05-02 생세포를 포함하는 생물학적 약물을 처리하기 위한 방법

Publications (2)

Publication Number Publication Date
KR20140043367A KR20140043367A (ko) 2014-04-09
KR102229108B1 true KR102229108B1 (ko) 2021-03-18

Family

ID=47108026

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020197020882A Active KR102202460B1 (ko) 2011-05-03 2012-05-02 생세포를 포함하는 생물학적 약물을 처리하기 위한 방법
KR1020147019539A Withdrawn KR20140099328A (ko) 2011-05-03 2012-05-02 생세포를 포함하는 생물학적 약물을 처리하기 위한 용기 또는 주사기
KR1020137032016A Active KR102229108B1 (ko) 2011-05-03 2012-05-02 생세포를 포함하는 생물학적 약물을 처리하기 위한 방법

Family Applications Before (2)

Application Number Title Priority Date Filing Date
KR1020197020882A Active KR102202460B1 (ko) 2011-05-03 2012-05-02 생세포를 포함하는 생물학적 약물을 처리하기 위한 방법
KR1020147019539A Withdrawn KR20140099328A (ko) 2011-05-03 2012-05-02 생세포를 포함하는 생물학적 약물을 처리하기 위한 용기 또는 주사기

Country Status (17)

Country Link
US (4) US10350242B2 (enExample)
EP (1) EP2704741B1 (enExample)
JP (3) JP5934783B2 (enExample)
KR (3) KR102202460B1 (enExample)
CN (2) CN103732247A (enExample)
AU (1) AU2012250794B2 (enExample)
BR (1) BR112013028257B1 (enExample)
CA (1) CA2838041C (enExample)
DK (1) DK2704741T3 (enExample)
ES (1) ES2648136T3 (enExample)
HU (1) HUE034995T2 (enExample)
IL (1) IL229176B (enExample)
PH (1) PH12013502253A1 (enExample)
PL (1) PL2704741T3 (enExample)
PT (1) PT2704741T (enExample)
SG (1) SG194774A1 (enExample)
WO (1) WO2012151266A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160095307A1 (en) 2014-10-07 2016-04-07 NuTech Medical, Inc. Method and composition for hypothermic storage of placental tissue
WO2016075542A1 (en) * 2014-11-11 2016-05-19 Macrocure, Ltd. Methods for extended storage of activated leukocyte compositions
JP6814593B2 (ja) * 2016-10-14 2021-01-20 株式会社 バイオミメティクスシンパシーズ 幹細胞及び投与システム
WO2020088631A1 (en) 2018-11-01 2020-05-07 Gracell Biotechnologies (Shanghai) Co., Ltd. Compositions and methods for t cell engineering
JP2022519154A (ja) * 2018-12-07 2022-03-22 グレイセル・バイオテクノロジーズ（シャンハイ）カンパニー・リミテッド 免疫療法のための組成物および方法
TW202110463A (zh) * 2019-05-15 2021-03-16 美商永生生技股份有限公司 高濃度細胞包裝和運送
EP4261242A4 (en) 2020-12-10 2024-11-06 Agc Inc. OXYALKYLENE POLYMER, PROCESS FOR PRODUCING SAME, CURABLE COMPOSITION AND CURED PRODUCT
KR20230154796A (ko) 2021-03-12 2023-11-09 에이지씨 가부시키가이샤 경화성 조성물 및 경화물
WO2023282298A1 (ja) 2021-07-07 2023-01-12 Ａｇｃ株式会社 硬化性組成物、硬化物、接着剤、及びシーリング材
JPWO2023190640A1 (enExample) * 2022-03-30 2023-10-05
DE112023002011T5 (de) 2022-04-22 2025-02-20 AGC Inc. Aushärtbare zusammensetzung und ausgehärtetes produkt
WO2023204064A1 (ja) 2022-04-22 2023-10-26 Ａｇｃ株式会社 硬化性組成物及びその硬化物
EP4516821A1 (en) 2022-04-27 2025-03-05 Agc Inc. Production method for reactive silicon group-containing organic polymer
CN119072501A (zh) 2022-04-27 2024-12-03 Ａｇｃ株式会社 含反应性硅基团的有机聚合物的制造方法
WO2023233962A1 (ja) 2022-06-03 2023-12-07 Ａｇｃ株式会社 接着剤組成物及び物品

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030175272A1 (en) 2002-03-07 2003-09-18 Medcell Biologics, Inc. Re-activated T-cells for adoptive immunotherapy

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2439003A1 (fr) 1978-10-20 1980-05-16 Anvar Nouvelles pieces d'osteosynthese, leur preparation et leur application
US5766920A (en) 1982-08-11 1998-06-16 Cellcor, Inc. Ex vivo activation of immune cells
AU7873187A (en) 1986-08-08 1988-02-24 University Of Minnesota Method of culturing leukocytes
AU2635088A (en) 1987-12-04 1989-06-08 Du Pont Merck Pharmaceutical Company, The Immobilized interleukin 2 and interleukin 2 containing a carboxyl-terminal extension
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US5126132A (en) 1989-08-21 1992-06-30 The United States Of America As Represented By The Department Of Health And Human Services Tumor infiltrating lymphocytes as a treatment modality for human cancer
US5728388A (en) 1989-10-03 1998-03-17 Terman; David S. Method of cancer treatment
US6204058B1 (en) 1992-02-07 2001-03-20 Vasogen Ireland Limited Treatment of autoimmune diseases
WO1994012196A1 (en) 1992-11-25 1994-06-09 Tanox Biosystems, Inc. Conjugates and constructs including anti-cd28 and anti-cd3 binding molecules
DE69430315T2 (de) 1993-08-06 2002-11-21 Epimmune, Inc. Methoden zur (ex vivo) therapie mittels peptid - bestueckten antigen - praesentierenden zellen zur aktivierung von ctl
IL107483A0 (en) 1993-11-03 1994-02-27 Yeda Res & Dev Bone marrow transplantation
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
DK0814838T3 (da) 1995-03-08 2003-09-15 Scripps Research Inst Antigenpræsenterende system og aktivering af T-celler
DE19545257A1 (de) 1995-11-24 1997-06-19 Schering Ag Verfahren zur Herstellung von morphologisch einheitlichen Mikrokapseln sowie nach diesem Verfahren hergestellte Mikrokapseln
PT969865E (pt) 1996-05-23 2007-02-28 Scripps Research Inst Sistemas de apresentação de antigénio da classe ii do mhc e métodos para activação de células t cd4+
US5753506A (en) 1996-05-23 1998-05-19 Cns Stem Cell Technology, Inc. Isolation propagation and directed differentiation of stem cells from embryonic and adult central nervous system of mammals
DE69718029T2 (de) 1996-10-11 2003-10-16 The Regents Of The University Of California, Oakland Krebs immuntherapie unter verwendung von tumorzellen kombiniert mit lymphozytmischungen
CA2274004A1 (en) 1996-12-03 1998-06-11 Osteobiologics, Inc. Biodegradable polymeric film
EP0966523A1 (en) 1997-01-31 1999-12-29 Hemosol Inc. Method for the production of selected lymphocytes
US7282198B2 (en) * 1997-03-19 2007-10-16 The University Of Arkansas For Medical Sciences Immunotherapeutic methods targeted towards stratum corneum chymotryptic enzyme
WO1998053768A1 (en) 1997-05-30 1998-12-03 Osteobiologics, Inc. Fiber-reinforced, porous, biodegradable implant device
JP2001522806A (ja) 1997-11-10 2001-11-20 アーチ・デヴェロップメント・コーポレイション エクス・ビボ活性化ｔ細胞を用いる腫瘍および腫瘍細胞の処理方法
JP2001054563A (ja) 1999-07-12 2001-02-27 Isotis Bv 縫合糸
US7112576B1 (en) 1999-12-10 2006-09-26 Regents Of The University Of Minnesota Compositions and methods for cryopreservation of peripheral blood lymphocytes
AU4328801A (en) 2000-02-24 2001-09-03 Xcyte Therapies Inc Simultaneous stimulation and concentration of cells
US20030119185A1 (en) 2000-02-24 2003-06-26 Xcyte Therapies, Inc. Activation and expansion of cells
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
AU2001292564A1 (en) 2000-08-31 2002-03-13 Emory University A method of transplantation using chemotherapy-treated allogeneic cells that enhance immune responses without graft versus host disease
US6626950B2 (en) 2001-06-28 2003-09-30 Ethicon, Inc. Composite scaffold with post anchor for the repair and regeneration of tissue
US20040258661A1 (en) 2001-10-31 2004-12-23 Daniel Fowler Generation of use of tc1 and tc2 cells
WO2003053216A2 (en) 2001-12-06 2003-07-03 University Of Washington Biodegradable, porous structures useful for growing living tissue, and methods of manufacture
US20030170238A1 (en) * 2002-03-07 2003-09-11 Gruenberg Micheal L. Re-activated T-cells for adoptive immunotherapy
DE10230223A1 (de) 2002-07-04 2004-01-22 Tegenero Ag Mikropartikel mit CD28-spezifischen monoklonalen Antikörpern
US7402431B2 (en) 2004-03-01 2008-07-22 Immunovative Therapies, Ltd. T-cell therapy formulation
US7435592B2 (en) 2003-05-13 2008-10-14 Immunovative Therapies, Ltd. Compositions for allogeneic cell therapy
US7371228B2 (en) 2003-09-19 2008-05-13 Medtronic Vascular, Inc. Delivery of therapeutics to treat aneurysms
US7592431B2 (en) 2004-02-26 2009-09-22 Immunovative Therapies, Ltd. Biodegradable T-cell Activation device
PL2573166T3 (pl) 2004-02-26 2016-11-30 Sposoby otrzymywania komórek T do terapii komórkowej
US7446099B2 (en) 2004-02-27 2008-11-04 Nitto Denko Corporation Compositions and methods for biodegradable polymer-peptide mediated transfection
CA2530514C (en) 2004-03-01 2017-01-31 Immunovative Therapies, Ltd. Cell therapy formulation method and composition
CA2557436A1 (en) 2004-03-05 2005-09-29 The Trustees Of Columbia University In The City Of New York Polymer-ceramic-hydrogel composite scaffold for osteochondral repair
TW200726474A (en) 2005-07-15 2007-07-16 Cognate Therapeutics Inc The immunophenotype and immunogenicity of human adipose derived cells
EP1792979A1 (en) * 2005-12-01 2007-06-06 Stiftung Caesar Center of Advanced European Studies and Research Cell culture system for the enrichment and expansion of stem cells
WO2009111638A1 (en) * 2008-03-05 2009-09-11 Baxter International Inc. Compositions and methods for drug delivery

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030175272A1 (en) 2002-03-07 2003-09-18 Medcell Biologics, Inc. Re-activated T-cells for adoptive immunotherapy

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Journal of Immunotherapy, Volume 32, Pages 169-180(2009)*

Also Published As

Publication number Publication date
DK2704741T3 (da) 2017-11-27
CA2838041A1 (en) 2012-11-08
US20190350976A1 (en) 2019-11-21
PL2704741T3 (pl) 2018-02-28
EP2704741A1 (en) 2014-03-12
US20230218672A1 (en) 2023-07-13
US10350242B2 (en) 2019-07-16
JP2017039728A (ja) 2017-02-23
CN103732247A (zh) 2014-04-16
BR112013028257A2 (pt) 2017-01-17
US20130101562A1 (en) 2013-04-25
AU2012250794A1 (en) 2013-12-12
AU2012250794B2 (en) 2015-11-05
AU2012250794A8 (en) 2013-12-19
KR20140099328A (ko) 2014-08-11
JP6006288B2 (ja) 2016-10-12
CN108261423B (zh) 2021-01-08
PH12013502253A1 (en) 2019-11-29
JP5934783B2 (ja) 2016-06-15
WO2012151266A1 (en) 2012-11-08
CA2838041C (en) 2018-09-25
KR20190090030A (ko) 2019-07-31
HK1254754A1 (zh) 2019-07-26
HUE034995T2 (en) 2018-05-02
PT2704741T (pt) 2017-11-24
EP2704741B1 (en) 2017-08-23
BR112013028257B1 (pt) 2020-05-12
EP2704741A4 (en) 2014-11-19
SG194774A1 (en) 2013-12-30
JP6359059B2 (ja) 2018-07-18
US11648273B2 (en) 2023-05-16
IL229176B (en) 2020-03-31
JP2014517830A (ja) 2014-07-24
KR20140043367A (ko) 2014-04-09
KR102202460B1 (ko) 2021-01-14
CN108261423A (zh) 2018-07-10
ES2648136T3 (es) 2017-12-28
IL229176A0 (en) 2013-12-31
US20230226112A1 (en) 2023-07-20
JP2015091848A (ja) 2015-05-14

Similar Documents

Publication Publication Date Title
KR102229108B1 (ko) 생세포를 포함하는 생물학적 약물을 처리하기 위한 방법
US20240067929A1 (en) Devices and methods for isolating tumor infiltrating lymphocytes and uses thereof
US20100233192A1 (en) Manufacturing Method of Activated Lymphocytes for Immunotherapy
Davis et al. Interleukin-7 permits Th1/Tc1 maturation and promotes ex vivo expansion of cord blood T cells: a critical step toward adoptive immunotherapy after cord blood transplantation
JP2024500748A (ja) 腫瘍浸潤リンパ球の処理
KR102888036B1 (ko) 면역 세포 제공 방법
TWI682996B (zh) 處理含有活細胞之生物藥物的方法
HK1254754B (zh) 用於加工含有活细胞的生物药物的方法
HK1195873A (en) Methods for handling biological drugs containing living cells

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20131202

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20140714

A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20170411

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20180820

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20190227

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20180820

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20190227

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20181018

Comment text: Amendment to Specification, etc.

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20190422

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20190326

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20190227

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20181018

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20180820

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20190717

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20190422

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Patent event date: 20190227

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Appeal identifier: 2019101002400

Request date: 20190717

J301 Trial decision

Free format text: TRIAL NUMBER: 2019101002400; TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20190717

Effective date: 20201130

PJ1301 Trial decision

Patent event code: PJ13011S01D

Patent event date: 20201130

Comment text: Trial Decision on Objection to Decision on Refusal

Appeal kind category: Appeal against decision to decline refusal

Request date: 20190717

Decision date: 20201130

Appeal identifier: 2019101002400

PS0901 Examination by remand of revocation
GRNO Decision to grant (after opposition)
PS0701 Decision of registration after remand of revocation

Patent event date: 20210104

Patent event code: PS07012S01D

Comment text: Decision to Grant Registration

Patent event date: 20201130

Patent event code: PS07011S01I

Comment text: Notice of Trial Decision (Remand of Revocation)

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20210311

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20210312

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20240228

Start annual number: 4

End annual number: 4